Psyence Biomedical Ltd.’s Free Cash Flow at a glance
Psyence Biomedical Ltd. reports free cash flow of -$3.7M for Mar 2025. The prior period recorded -$3.0M (Mar 2024). Year over year the metric moved −$793,021 (−26.9%). The rolling three-period average stands at -$2.4M. Data last refreshed Nov 20, 2025, 7:10 PM.
Latest reading
-$3.7M · Mar 2025
YoY movement
−$793,021 (−26.9%)
Rolling average
-$2.4M
Current Free Cash Flow
-$3.7M
−$793,021
−26.9%
Rolling average
-$2.4M
Latest Value
-$3.7M
Mar 2025
YoY Change
−$793,021
Absolute
YoY Change %
−26.9%
Rate of change
3-Period Avg
-$2.4M
Smoothed
Narrative signal
Psyence Biomedical Ltd.’s free cash flow stands at -$3.7M for Mar 2025. Year-over-year, the metric shifted by −$793,021, translating into a −26.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow shapes Psyence Biomedical Ltd.'s story
As of Mar 2025, Psyence Biomedical Ltd. reports free cash flow of -$3.7M. Track free cash flow trends, reinvestment capacity, and balance sheet flexibility using historical cash flow statements.
Why free cash flow matters
Free cash flow underpins dividends, buybacks, debt reduction, and reinvestment. It is a critical input for equity valuations and credit analysis.
Evaluating free cash flow volatility
Consider cash flow stability alongside growth. Large swings can signal heavy capital investment cycles or working capital shifts that may not repeat.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Psyence Biomedical Ltd. (PBM) FAQs
Answers tailored to Psyence Biomedical Ltd.’s free cash flow profile using the latest Financial Modeling Prep data.
What is Psyence Biomedical Ltd.'s current free cash flow?
As of Mar 2025, Psyence Biomedical Ltd. reports free cash flow of -$3.7M. This reading reflects the latest filings and price data for PBM.
How is Psyence Biomedical Ltd.'s free cash flow trending year over year?
Year-over-year, the figure shifts by −$793,021 (−26.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PBM.
Why does free cash flow matter for Psyence Biomedical Ltd.?
Free cash flow reflects the cash a company generates after funding operations and capital expenditures. For Psyence Biomedical Ltd., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Psyence Biomedical Ltd.'s free cash flow above its recent average?
Psyence Biomedical Ltd.'s rolling three-period average sits at -$2.4M. Comparing the latest reading of -$3.7M to that baseline highlights whether momentum is building or fading for PBM.
How frequently is Psyence Biomedical Ltd.'s free cash flow refreshed?
Data for PBM was last refreshed on Nov 20, 2025, 7:10 PM and updates automatically every 24 hours, keeping your valuation inputs current.